Evidence-Based Summary
Insulin is the hormone that moves glucose out of the blood; as a medicine it acts whatever the current glucose level, so too much can cause hypoglycemia. It is essential in type 1 diabetes, and in the DCCT trial intensive insulin therapy cut retinopathy risk by 76% in the primary-prevention group but raised severe hypoglycemia two- to threefold. GLP-1 is a gut hormone released after meals. It is a main driver of the incretin effect: the larger insulin response to glucose taken by mouth than to the same blood-glucose rise given by vein. In healthy people, incretins accounted for about 73% of the insulin response to oral glucose; in type 2 diabetes this fell to about 36%. GLP-1 increases insulin release only while glucose is raised: in a 1993 infusion study, insulin fell back toward baseline as glucose normalized. That is why GLP-1-based drugs, used without insulin or sulfonylureas, carry much less hypoglycemia risk than insulin. In SUSTAIN 4, confirmed or severe hypoglycemia occurred in 4% and 6% with semaglutide versus 11% with insulin glargine. Native GLP-1 is not a medicine: it is inactivated within minutes, and it cannot replace insulin when beta cells are lost.
Quick Comparison: Insulin vs GLP-1
A high-level comparison of molecule class, molecular receptor targets, FDA regulatory approvals, and verified clinical programs.
| Feature | Insulin | GLP-1 |
|---|---|---|
| Class | Pancreatic beta-cell hormone; approved medicine (human insulin and analogues) | Gut incretin hormone; the template for GLP-1 receptor agonist drugs |
| Structure | 51 amino acids in two chains (A chain 21, B chain 30) joined by disulfide bonds | 30 amino acids (main active form, GLP-1(7-36) amide) |
| Target receptor or mechanism | Insulin receptor (a tyrosine kinase) on muscle, fat and liver; acts directly | GLP-1 receptor on beta cells and elsewhere; increases the body's own insulin release |
| Depends on glucose level | No; lowers glucose even when it is already normal or low | Yes; insulin-releasing effect fades as glucose normalizes |
| Needs working beta cells | No | Yes |
| How it is given or used | Injection under the skin (once daily or more often, by product), insulin pump, or intravenous in hospital | Not a product; in research, intravenous or subcutaneous infusion |
| U.S. regulatory status | FDA-approved (many products, regulated as biologics) | Not an approved medicine; engineered GLP-1 analogues are approved |
| Direct comparison | None with native GLP-1; GLP-1 drugs have been compared with insulin glargine (SUSTAIN 4) | None |
| Strongest human evidence | DCCT and UKPDS 33: fewer microvascular complications with intensive control | Short infusion studies; outcome evidence belongs to engineered analogues |
| Main safety concerns or unknowns | Hypoglycemia (most common adverse reaction), weight gain, hypokalemia | No product label; long-term safety of the native hormone not studied |
| WADA status (2026) | Prohibited (Section S4, metabolic modulators) unless a Therapeutic Use Exemption is granted | Check the current WADA Prohibited List |
Acting on Tissues Versus Acting on the Pancreas
Insulin is the end signal: it binds its receptor on muscle, fat and liver cells and drives glucose uptake and storage. GLP-1 sits one step upstream: it tells beta cells to release more of their own insulin, and the effect depends on glucose already being raised. GLP-1 also lowers glucagon, slows stomach emptying and reduces appetite.
Insulin
Primary Target: Insulin receptor (tyrosine kinase)
Affinity Profile: Endogenous ligand; acts on most tissues
Binding activates the receptor's kinase, which signals through IRS-1, PI3-kinase and Akt to move GLUT4 glucose transporters to the cell surface. Glucose then enters muscle and fat cells regardless of how high or low blood glucose is, which is why an excess of insulin causes hypoglycemia.
GLP-1
Primary Targets: GLP-1 receptor (G protein-coupled)
Affinity Profile: Endogenous ligand; rapidly inactivated by DPP-4
Receptor activation raises cAMP in beta cells, which amplifies insulin release triggered by glucose. When glucose falls toward normal, the trigger weakens and the extra insulin release stops. The enzyme DPP-4 inactivates native GLP-1 within minutes.
An Approved Medicine and a Research Hormone
Checked 18 October 2026 against Drugs@FDA and DailyMed. An approval belongs to a named product, formulation and population.
Insulin Status & Formulations
Insulin products are FDA-approved and are regulated as biologics. Long-acting analogues such as Lantus (insulin glargine) are indicated to improve glycemic control in adults and children with diabetes; Lantus is not recommended for diabetic ketoacidosis. Each insulin product has its own label, onset and duration.
GLP-1 Status & Formulations
Native GLP-1 is an endogenous hormone, not a marketed medicine. It is used in clinical research, mostly by infusion. The first engineered GLP-1 receptor agonist, exenatide (Byetta), was approved in 2005.
Critical Regulatory Distinction
Approved GLP-1 receptor agonists (for example exenatide, liraglutide, dulaglutide, semaglutide) and the dual GIP/GLP-1 agonist tirzepatide are separate medicines with their own labels. None is approved for type 1 diabetes, and none replaces insulin when beta cells are lost.
Outcome Trials for Insulin, Physiology Studies for GLP-1
Insulin's evidence comes from large randomized trials of glucose control. Native GLP-1's evidence comes from short physiology and infusion studies. Trials of GLP-1 drugs against insulin test engineered analogues, not the native hormone.
Insulin: Clinical Evidence Overview
The DCCT randomized 1,441 people with type 1 diabetes for a mean of 6.5 years. Intensive insulin therapy reduced the risk of developing retinopathy by 76% in the primary-prevention group and, across both groups, reduced microalbuminuria by 39% and clinical neuropathy by 60%; severe hypoglycemia rose two- to threefold. UKPDS 33 randomized 3,867 adults with newly diagnosed type 2 diabetes: intensive control with sulphonylureas or insulin lowered microvascular endpoints by 25% over 10 years but did not significantly reduce macrovascular disease, with more hypoglycaemia and 4.0 kg more weight gain in the insulin group.
GLP-1: Clinical Evidence Overview
Nauck and colleagues (1986) showed the incretin effect is reduced in type 2 diabetes: incretins contributed about 73% of the insulin response to oral glucose in 8 healthy controls versus about 36% in 14 people with type 2 diabetes. In 1993, intravenous GLP-1 brought fasting glucose to normal within 4 hours in 10 adults with type 2 diabetes, and insulin returned toward baseline once glucose normalized. A 6-week continuous subcutaneous infusion in 20 adults lowered HbA1c by 1.3 percentage points and weight by 1.9 kg versus saline.
Curated Clinical Evidence Table
A curated selection of the primary studies behind each compound’s evidence profile. Results from different studies are not directly comparable.
| Study & Citation | Population | Comparison & Dosing | Duration | Main Endpoint | Key Finding | Methodological Limitations |
|---|---|---|---|---|---|---|
| DCCT (DCCT Research Group, NEJM 1993) | 1,441 people with type 1 diabetes | Intensive vs conventional insulin therapy | Mean 6.5 years | Retinopathy, nephropathy, neuropathy | Retinopathy risk −76% (primary prevention); microalbuminuria −39%; clinical neuropathy −60%. | Severe hypoglycemia increased two- to threefold with intensive therapy. |
| UKPDS 33 (UKPDS Group, Lancet 1998) | 3,867 adults with newly diagnosed type 2 diabetes | Intensive control (sulphonylureas or insulin) vs conventional treatment | 10 years | Diabetes-related complications | Microvascular endpoints −25%; no significant reduction in macrovascular disease. | More hypoglycaemia; 4.0 kg weight gain in the insulin group. |
| Incretin effect in type 2 diabetes (Nauck et al., Diabetologia 1986) | 14 adults with type 2 diabetes and 8 matched controls | Oral glucose vs matched intravenous glucose | Single test days | Share of insulin response due to incretins | About 73% in controls vs about 36% in type 2 diabetes. | Small physiology study; does not separate GLP-1 from GIP. |
| GLP-1 infusion study (Nauck et al., Diabetologia 1993) | 10 adults with poorly controlled type 2 diabetes | Intravenous GLP-1 vs placebo infusion | Single infusion (hours) | Fasting glucose, insulin, glucagon | Glucose normalized within 4 hours; insulin returned toward baseline as glucose normalized. | Very small; acute study. |
| Six-week GLP-1 infusion (Zander et al., Lancet 2002) | 20 adults with type 2 diabetes | Continuous subcutaneous GLP-1 vs saline | 6 weeks | HbA1c, fasting glucose, weight | HbA1c −1.3 points; weight −1.9 kg. | Alternate rather than random assignment; small. |
| SUSTAIN 4 (Aroda et al., Lancet Diabetes Endocrinol 2017) | 1,089 insulin-naive adults with type 2 diabetes on metformin with or without a sulfonylurea | Semaglutide (GLP-1 analogue; two dose groups) vs insulin glargine | 30 weeks | HbA1c; body weight; hypoglycemia | HbA1c −1.21 and −1.64 vs −0.83 points; weight −3.47 and −5.17 kg vs +1.15 kg; confirmed or severe hypoglycemia 4% and 6% vs 11%. | Tests an engineered analogue, not native GLP-1; open-label; funded by Novo Nordisk. |
Why Hypoglycemia Risk Differs
Insulin's main risk follows from how it works: it keeps lowering glucose after glucose is normal. GLP-1's insulin-releasing effect switches off as glucose falls, so hypoglycemia is uncommon unless it is combined with insulin or a sulfonylurea. Native GLP-1 has no label; the GLP-1 column describes the hormone and, where stated, its drug analogues.
| Safety Consideration | Insulin | GLP-1 |
|---|---|---|
| Product label | Yes; no boxed warning on basal insulin labels such as Lantus | None; not a marketed product |
| Hypoglycemia | Most common adverse reaction of insulin; severe episodes can cause seizures or death | Uncommon alone; risk rises when GLP-1 drugs are combined with insulin or sulfonylureas |
| Body weight | Weight gain (4.0 kg in the UKPDS 33 insulin group) | Weight loss (1.9 kg in a 6-week infusion study; larger with long-acting analogues) |
| Other label warnings or effects | Hypokalemia; hypersensitivity; never share pens or needles; fluid retention with thiazolidinediones | Nausea and other gastrointestinal effects are the most common adverse events of GLP-1 drugs (21% to 22% nausea with semaglutide in SUSTAIN 4) |
| Loss of beta cells (type 1 diabetes) | Essential replacement | Cannot work without beta cells to release insulin |
What Insulin and GLP-1 Have in Common
Where the two compounds overlap in biology, evidence or regulatory context.
Both lower blood glucose
Insulin does it directly; GLP-1 does it by increasing insulin and reducing glucagon.
Both are peptide hormones
Both are made in the body and both are broken down if swallowed, so medicines based on them are mainly injected.
Meal-time hormones
Both rise after a meal; GLP-1 from the gut helps trigger the insulin response.
Key Scientific & Clinical Differences
Meaningful distinctions in mechanism, strength of evidence, safety and regulatory status.
Glucose dependence
GLP-1's effect on insulin fades as glucose normalizes; insulin keeps acting, which explains the difference in hypoglycemia risk.
Beta-cell requirement
GLP-1 needs working beta cells; insulin replaces what failing or absent beta cells cannot make.
Regulatory position
Insulin itself is an approved medicine; native GLP-1 is a research hormone whose engineered analogues are approved.
Scientific Comparison vs Clinical Recommendations
InsidePeptides compares scientific evidence, receptor pharmacology, and official regulatory documents to advance public and professional understanding. We do not determine which compound is appropriate for an individual patient, rank medications with arbitrary scores, or recommend initiating or switching treatments.
Decisions about any medicine require a licensed healthcare professional who can weigh personal medical history, contraindications, interactions and monitoring needs. Unapproved peptides have no established safe use, and products sold as “research chemicals” are not the preparations studied in clinical research.
Approved Uses vs Online Claims
A critical scientific distinction between verified, FDA-approved clinical uses and unverified claims circulating on social media and vendor platforms.
GLP-1 drugs can replace insulin in type 1 diabetes
Not supportedNo GLP-1 receptor agonist is approved for type 1 diabetes.
GLP-1 works by making beta cells release insulin. In type 1 diabetes those cells are destroyed, and stopping insulin can lead to diabetic ketoacidosis.
GLP-1 drugs never cause low blood sugar
Partly trueGLP-1 drug labels warn about hypoglycemia with insulin or insulin secretagogues.
Their insulin effect is glucose-dependent, so risk is low alone. Combined with insulin or a sulfonylurea, hypoglycemia, including severe hypoglycemia, can occur.
Natural GLP-1 boosters work like GLP-1 medicines
Not establishedOnly specific engineered GLP-1 receptor agonists are FDA-approved.
Native GLP-1 lasts minutes; drug trials test engineered, long-acting molecules at exposures food or supplements do not reproduce.
Evidence Strength Across Clinical Domains
InsidePeptides evaluates scientific certainty at the claim level. Because clinical evidence varies significantly depending on the therapeutic endpoint evaluated, each domain is assessed independently.
Lowering blood glucose
Insulin has decades of randomized trials; native GLP-1 has small infusion studies, while its analogues have strong evidence.
Long-term complications
DCCT and UKPDS 33 for insulin; no long-term studies of the native hormone.
Incretin physiology
Controlled human physiology studies define GLP-1's glucose-dependent role; insulin is the downstream effector, not an incretin.
Direct comparison
No trial compares native GLP-1 with insulin; trials such as SUSTAIN 4 test analogues.
What Research Still Doesn’t Tell Us
Identifying open scientific questions, pending active-comparator trials, and areas where long-term clinical data remain incomplete.
Restoring the incretin effect
Why the incretin effect is reduced in type 2 diabetes, and how far treatment can restore it, is not fully settled.
Adding GLP-1 drugs to insulin in type 1 diabetes
Whether GLP-1-based drugs help as an add-on to insulin in type 1 diabetes is unresolved, and no such use is approved.
Native hormone versus drug exposure
Brief meal-time GLP-1 signals and continuous drug exposure differ; results from one do not transfer directly to the other.
Related Compound Profiles
Individual profiles provide full molecular datasheets, CAS numbers, preclinical histories, and compound monographs.
Related Educational Resources
Scientific & Regulatory References
Every pharmacological mechanism, clinical trial result, and regulatory approval cited on this page is traceable to official FDA prescribing documentation, ClinicalTrials.gov registries, or peer-reviewed medical publications.
-
Human physiology study
Reduced incretin effect in type 2 (non-insulin-dependent) diabetes14 people with type 2 diabetes and 8 matched controls.
-
Human infusion study
Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients
-
Parallel-group pilot study
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study
-
Physiology review
The incretin system in healthy humans: The role of GIP and GLP-1
-
Review
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
-
Cell biology review
Mechanisms of Insulin Action and Insulin Resistance
-
Landmark randomized controlled trial
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
-
Landmark randomized controlled trial
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
-
Randomized controlled trial · Active comparator
Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial1,089 adults; 30 weeks; funded by Novo Nordisk.
-
Official U.S. prescribing information
Lantus (insulin glargine) injection, current U.S. labelSanofi label; checked 18 October 2026.
-
FDA approval record
Drugs@FDA: Byetta (Exenatide) NDA 021773